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Acetyl-CoA carboxylase purified from isolated hepatocytes is activated dramatically by protein phosphatase treatment, 
concomitant with a reduction of the phosphate content from 3.7 to 1.1 mol/subunit. Glucagon treatment of the cells 
produces a further inactivation of the enzyme that is totally reversed by phosphatase treatment, and is associated with 
an increase in phosphate content of 0.8 mol/subunit, distributed in two peptides which contain the sites phosphorylated 
in vitro by the cyclic AMP-dependent and AMP-activated protein kinases. Sequencing of these peptides shows that the 
low activity of acetyl-CoA carboxylase is due to phosphorylation by the AMP-activated protein kinase, and not cyclic 
AMP-dependent protein kinase, even after glucagon treatment. 
Acetyl-CoA carboxylase; Hepatocyte; Glucagon; AMP-activated protein kinase; cyclic AMP-dependent protein kinase; (Rat) 
1. INTRODUCTION 
Acetyl-CoA carboxylase catalyses the first step 
committed to fatty acid biosynthesis, and is known 
to be regulated in vitro by allosteric effecters (e.g. 
activation by citrate) and by phosphorylation at 
multiple sites by a variety of protein kinases [ 1,2], 
including cyclic AMP-depdendent protein kinase 
[3,4] and a novel protein kinase from rat liver 
which also phosphorylates HMG-CoA reductase, 
and which we have termed the AMP-activated pro- 
tein kinase [5,6]. Recently we have defined by 
amino acid sequencing the sites on acetyl-CoA car- 
boxylase at which these two kinases inactivate the 
enzyme [7]. Phosphorylation by cyclic AMP- 
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dependent protein kinase produces an increase in 
Xa for citrate and a modest depression of I’,,,, and 
is associated with the phosphorylation of sites 1 
(RMSF) and 2 (SSMSGLHLVK). Phosphorylation 
by the AMP-activated protein kinase also increases 
the Ka for citrate but produces a much more 
dramatic decrease in I’,,,, and is associated with 
phosphorylation of sites 1 and 3, the latter 
(SSMSGLHLVK) being immediately adjacent to 
site 2 [7]. 
We have shown that hormones which increase 
cyclic AMP levels (glucagon in hepatocytes [8], 
glucagon and adrenaline in adipocytes [9,10]) lead 
to both inactivation and phosphorylation of 
acetyl-CoA carboxylase, although the enzyme is 
already in a highly phosphorylated form of low 
specific activity in unstimulated cells, particularly 
in hepatocytes. Phosphorylation in response to 
glucagon/adrenaline occurred within the same 
peptides which are phosphorylated by cyclic AMP- 
dependent protein kinase in vitro [8-IO]. However, 
since the AMP-activated protein kinase phospho- 
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rylates sites within these same peptides, in one case 
at a different serine residue, it was not clear which 
of the two kinases was responsible for the phos- 
phorylation and low activity of the enzyme in basal 
or stimulated cells. We have therefore re-examined 
this question by sequencing of phosphopeptides 
derived from 32P-labelled, isolated hepatocytes. 
2. MATERIALS AND METHODS 
Sources of materials have been described [7,8,11]. 
Hepatocytes were isolated from starved-refed rats in mid-dark 
phase, preincubated initially for 30 min, then for 60 min with 
or without [“PIphosphate, and then treated with or without 
glucagon (lo-’ M) for 15 min [8]. Acetyl-CoA carboxylase was 
purified by avidin-Sepharose chromatography as described [8] 
except that the buffers contained the protein phosphatase in- 
hibitor Na pyrophosphate (5 mM) as well as NaF. For ex- 
periments in which the purified acetyl-CoA carboxylase was 
treated with protein phosphatase, the avidin-Sepharose column 
was washed with 5 vols buffer without NaF and pyrophosphate 
immediately before elution with the same buffer plus 2 mM 
biotin. The purified enzyme was treated with protein 
phosphatase-1 (400 U/ml [ll]) in the biotin buffer in the 
presence of 1 mM MnClz for 45 min at 37°C. Acetyl-CoA car- 
boxylase was assayed using the %-fixation assay [S]. For pro- 
teolytic digestion, the enzyme was precipitated with 300 pg 
bovine serum albumin using 55% saturated ammonium 
sulphate. The precipitate was collected in a microcentrifuge and 
resuspended in 50 mM Na Hepes (pH 7.0), 50 mM NaCI, 50 
mM NaF, 1 mM EDTA, 1 mM dithiothreitol, and digested for 
16 h at 37°C with trypsin (1 : 50 by wt), chymotrypsin (1 :50), 
or both proteinases together. The reaction was stopped by ad- 
ding trichloroacetic acid to 10% (w/v). Undigested material was 
removed by centrifugation, trichloroacetic acid removed by 
ether extraction, and peptides were separated by reversed-phase 
HPLC in 0.1% (v/v) trifluoroacetic acid Ii]. Automated Ed- 
man degradation was carried out on an Applied Biosystems 
470A gas phase sequencer after derivatization of phosphoserine 
with ethanethiol [12]. Alternatively, samples were run without 
derivatization, and after various cycles of degradation, sections 
of the filter were removed 1131, and the nature of the bound 32P 
radioactivity analysed by thin-layer electrophoresis at pH 1.9 
[71. 
3. RESULTS 
3.1. Effect of protein phosphatase treatment on 
acetyl-CoA carboxylase purified from control 
or glucagon-treated hepatocytes 
Fig.1 shows that, as reported previously [8], 
glucagon treatment of isolated hepatocytes pro- 
duced an inactivation of acetyl-CoA carboxylase 
which was stable during purification to 
Control + phosphatase 
[citrate] (mM) 
Fig. 1. Activity, expressed as a function of citrate concentration, 
of acetyl-CoA carboxylase purified from control (open 
symbols) or glucagon-treated (filled symbols) hepatocytes. 
Square symbols show the activity after protein phosphatase 
treatment of the purified enzymes. 
homogeneity in the presence of protein 
phosphatase inhibitors. In three experiments 
glucon decreased the vmax of the enzymes from 
0.97 -1- 0.24 to 0.45 -t 0.09 pmol/min per mg (mean 
f SE), while it increased the K, for the allosteric 
activator, citrate, from 5.65kO.86 to 8.07t-3.3 
mM. Fig.1 shows that protein phosphatase treat- 
ment dramatically activated enzymes from both 
control and glucagon-treated cells, so that their ac- 
tivities became indistinguishable. At a physiologi- 
cal citrate concentration (0.6 mM), the control 
enzyme was activated 13-fold and the ‘glucagon’ 
enzyme 26-fold (mean of 3 experiments). For con- 
trol and glucagon samples respectively, the V,,, 
values increased to 3.19kO.19 and 3.35 kO.06 
pmol/min per mg, and the Ka values decreased to 
1.1 kO.4 and 1.4kO.l mM. 
When cells were 32P-labelled for 60 min prior to 
hormone treatment, the inactivation produced by 
glucagon was found to be associated with a 
16k 2% (8) increase in the specific activity of 
purified acetyl-CoA carboxylase. In 2 experiments 
we estimated the actual phosphate content of the 
enzyme by determining the specific activity of the 
intracellular nucleotides, and obtained values of 
3.92 and 3.56 mol/subunit (control) and 4.71 and 
4.27 mol/subunit (glucagon), which are slightly 
lower than values obtained in a previous, more ex- 
tended series of measurements [8]. Protein 
phosphatase treatment reduced the phosphate con- 
tent to 1.1-1.3 mol/subunit in every case. 
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3.2. Phosphopeptide analysis of acetyl-CoA 
carboxylase from control and glucagon- 
treated hepatocytes 
Acetyl-CoA carboxylase purified from 32P- 
labelled, control or glucagon-treated hepatocytes 
was digested with proteinases and the radioactive 
phosphopeptides analysed by reversed-phase 
HPLC. Fig.2 shows that glucagon produced small 
increases in phosphorylation within a single tryptic 
peptide (Tl), or within two peptides generated by 
simultaneous digestion with trypsin plus 
chymotrypsin (TCI, TC2). Each of these peptides 
comigrated (fig.2) with previously sequenced pep- 
tides [7] containing sites phosphorylated by the 
cyclic AMP-dependent and AMP-activated protein 
kinases: Tl corresponds to the peptide 
SSMSGLHLVK, containing sites 2 and 3; TCl 
corresponds to the peptide SSMSGL, also contain- 
ing sites 2 and 3; and TC2 corresponds to the pep- 
tide RMSF, containing site 1. We have shown 
previously that glucagon increased 32P labelling of 
a single chymotryptic peptide, comigrating with 
the single major phosphopeptide (Cl) produced by 
chymotryptic digestion of acetyl-CoA carboxylase 
phosphorylated by cyclic AMP-dependent protein 
kinase [8]. Peptide Cl has now been shown by se- 
quencing to be identical with TC2 [7]. 
In the same 8 experiments in which the total 
specific activity of acetyl-CoA carboxylase in- 
creased by 16 f 2070, the increases in labelling of 
peptides TCl and TC2 were 28 f 6 and 40 f 5%, 
respectively. All of these effects of glucagon were 
significant (p<O.O5) by the paired t-test. 
3.3. Analysis of the serine residue phosphorylated 
within peptide Tl 
Since peptides Cl and TC2 are identical and 
contain a single phosphorylatable serine residue, it 
is clear from this and our previous studies [8] that 
glucagon treatment of hepatocytes (and adrenaline 
or glucagon treatment of adipocytes [lo]) increases 
phosphorylation of site 1. However, peptides Tl 
and TCl contain three serine residues, at least two 
of which (sites 2,3) can be phosphorylated by 
distinct protein kinases in vitro. Peptide Tl was 
purified from control hepatocytes and subjected to 
automated Edman degradation in the gas-phase se- 
quencer after derivatization with ethanethiol to 
convert phosphoseine to ethylcysteine [ 121. The 
results (not shown) confirmed that the peptide was 
CONTROL CONTROL 
.- -100 
- 80 
40 60 40 60 120 
Retention time (min) 
Fig.2. Reversed-phase HPLC analysis of 3ZP-labelled peptides derived from digestion of acetyl-CoA carboxylase by digestion with 
trypsin + chymotrypsin (left) or trypsin alone (right). Acetyl-CoA carboxylase was either purified from ‘*P-labelled, control or 
glucagon-treated hepatocytes, or was purified from lactating mammary gland and phosphorylated in vitro using [y-32P]ATP and the 
purified catalytic subunit of cyclic AMP-dependent protein kinase. 
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Cycle No: 1 2 3 4 5 6 1 2 3 4 5 6 
Residue released: S S M S G L S S M S G L 
Fig.3. Recovery of radioactivity eluted from the glass fibre filter after various cycles of Edman degradation of peptide Tl in the gas- 
phase sequencer. Peptide Tl was isolated from 32P-labelled, control or glucagon-treated hepatocytes. Samples were analysed by thin- 
layer electrophoresis at pH 1.9, and results are expressed as the % of the total radioactivity recovered migrating as free phosphate 
or as phosphopeptide. The total radioactivity recovered was 500-600 cpm (Cerenkov) in each case. 
identical with peptide Tl phosphorylated by cyclic 
AMP-dependent protein kinase, and the recovery 
of ethylcysteine in the 4th cycle showed that site 3 
was at least partially phosphorylated in the intact 
cells. To study this more quantitatively, we anal- 
ysed the underivatized peptides from control and 
glucagon-treated cells by the method of Wang et 
al. [13], in which sections of the filter containing 
aliquots of the sample are removed after various 
cycles of degradation, eluted, and the radioactive 
products analysed for the presence of phosphopep- 
tide or free phosphate. The results (fig.3) showed 
that only - 5% of the radioactivity was recovered 
as free phosphate in cycles 1 and 2, as against 
SO-90% after cycle 4. These results show that only 
site 3 (Ser-Ser-Met-Ser(P)-Gly-Leu) was signifi- 
cantly phosphorylated in Tl in both control and 
glucagon-treated hepatocytes. 
4. DISCUSSION 
Our results strongly suggest hat the low V,,, of 
acetyl-CoA carboxylase isolated from hepatocytes 
is due to phosphorylation at site 3 by the AMP- 
activated protein kinase. Of seven purified protein 
kinases with which we have demonstrated 
phosphorylation of acetyl-CoA carboxylase in 
vitro, the AMP-activated protein kinase is the only 
one which phosphorylates ite 3 [7], and the only 
one which produced a large (> 75%) depression of 
V max [5,6] similar to that observed in intact 
hepatocytes. Apart from a partial phosphorylation 
of site 1, the only other major phosphopeptide 
observed under basal conditions was peptide T4. 
Phosphorylation of this peptide increases in 
response to insulin and EGF [14], and we have 
shown by amino acid sequencing that, at least in 
isolated adipocytes, the sites phosphorylated in T4 
correspond to those phosphorylated in vitro by ca- 
sein kinase-2 and the calmodulin-dependent 
multiprotein kinase [15]. Neither of these protein 
kinases produces a significant change in the kinetic 
properties of acetyl-CoA carboxylase in vitro 
[16,17], and it therefore seems unlikely that 
phosphorylation within this peptide would explain 
the low basal activity of the enzyme. 
The finding that the increase in phosphorylation 
of acetyl-CoA carboxylase after glucagon treat- 
ment was confined to sites 1 and 3 was unexpected, 
and shows that the glucagon-mediated inactivation 
of acetyl-CoA carboxylase is due to changes at the 
sites phosphorylated by the AMP-activated protein 
kinase and not due to direct phosphorylation by 
the cyclic AMP-dependent protein kinase as we 
previously suggested [S]. Site 2 is not significantly 
phosphorylated in the isolated hepatocytes even 
after glucagon treatment, showing that acetyl-CoA 
carboxylase is not a substrate for cyclic AMP- 
dependent protein kinase in intact cells. Although 
acetyl-CoA carboxylase is a substrate for this 
kinase in vitro, at a protein substrate concentration 
of 2 PM it is phosphorylated at only - 10% of the 
rate of phosphorylase kinase [3], and sites 1 and 2 
contain only one N-terminal arginine residue 
rather than the two adjacent basic residues normal- 
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ly considered to be specificity determinants for this 
kinase [18]. 
How phosphorylation at sites 1 and 3 is 
stimulated by glucagon is not clear. Lent and Kim 
[19] reported that a hepatic acetyl-CoA carbox- 
ylase kinase they had purified was activated by 
phosphorylation by cyclic AMP-dependent protein 
kinase. Although the kinase of Lent and Kim ap- 
pears similar to the AMP-activated protein kinase 
in many respects, we have been unable to show ac- 
tivation of the AMP-activated protein kinase using 
purified cyclic AMP-dependent protein kinase. An 
alternative possibility is that glucagon could cause 
inhibition of protein phosphatases acting on either 
acetyl-CoA carboxylase or the AMP-activated pro- 
tein kinase or both. Possible mechanisms include 
inhibition of protein phosphatase-1 by inhibitor-l 
[18] or by phosphorylase [20]. Both of these are 
potent inhibitors of the phosphatase in their 
phosphorylated forms, into which they would be 
converted after glucagon treatment. It is however 
not certain that phosphatase-1, which appears in 
the cell to be largely bound to glycogen particles 
and/or membranes [ 181, is responsible for 
dephosphorylation of these substrates in vivo. 
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